Skip to main
QNCX

QNCX Stock Forecast & Price Target

QNCX Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Quince Therapeutics Inc is positioned positively due to its strategic agreements with the FDA, particularly the special protocol assessment (SPA) that supports the approval process for its lead program, eDSP, pending success in the Phase 3 NEAT trial. The company’s long-term safety data for eDSP in pediatric patients with Ataxia-Telangiectasia is notable, demonstrating a strong tolerability profile without significant corticosteroid-related toxicities, which enhances the credibility of the program as it advances. Overall, the promising results from previous trials and the company’s innovative drug delivery platform contribute to a favorable valuation outlook and reduced risk profile, positioning Quince Therapeutics for potential growth within the biopharmaceutical sector.

Bears say

Quince Therapeutics has faced a significant setback following the dismal results from its pivotal Phase 3 NEAT clinical trial for eDSP in Ataxia-Telangiectasia, which failed to meet both primary and secondary endpoints, leading to a substantial downgrade in market outlook. The management's decision to halt development of eDSP notably restricts the company's pipeline options, indicating a shift in focus from clinical development to financial sustainability. Furthermore, the company’s shares plummeted 92% after the trial results, underscoring the market's negative sentiment, while the absence of commercialization history and projected ongoing net losses exacerbate the financial risks associated with the stock.

QNCX has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quince Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quince Therapeutics Inc (QNCX) Forecast

Analysts have given QNCX a Buy based on their latest research and market trends.

According to 3 analysts, QNCX has a Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quince Therapeutics Inc (QNCX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.